Now showing items 1-3 of 3
MAO inhibitors and their wider applications: a patent review
(Taylor & Francis, 2018)
Introduction: Monoamine oxidase (MAO) inhibitors, after the initial ‘golden age’, are currently used as third-line antidepressants (selective MAO-A inhibitors) or clinically enrolled as co-adjuvants for neurodegenerative ...
Therapeutic potential of selectively targeting the α2c-adrenoceptor in cognition, depression, and schizophrenia: new developments and future perspective
(Frontiers Media, 2017)
α2A- and α2C-adrenoceptors (ARs) are the primary α2-AR subtypes involved in central nervous system (CNS) function. These receptors are implicated in the pathophysiology of psychiatric illness, particularly those associated ...
Novel monoamine oxidase inhibitors: a patent review (2012-2014)
(Taylor & Francis, 2015)
Introduction: Monoamine oxidase (MAO) inhibitors, despite the initial pharmacological interest, are used in clinic for their antidepressant effect and in the management of Parkinson symptoms, due to the established ...